prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, PATIENT HISTORY: DATE of LMP. DATE or LAST DELIVERY: PRE-OP DIAGNOSIS: CA L BREAST. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: LEFT MODIFIED RADICAL MASTECTOMY. CLINICAL HISTORY: MATERIAL SUBMITTED: LEFT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. Lt breast & axillary content. FINAL DIAGNOSIS: FINAL DIAGNOSIS: BREAST AND AXILLA, LEFT, MODIFIED RADICAL MASTECTOMY: - INFILTRATING DUCTAL CARCINOMA ("A2-A7"), 4.5 BY 4.5 BY 3.5 CM, NOTTINGHAM 6/9 (TUBULES 3, NUCLEI 2,. MITOSIS 1), WITH LYMPHOVASCULAR PERMEATION, INVOLVING THE DEEP DERMIS. DUCTAL CARCINOMA IN-SITU, SOLID TYPE, NUCLEAR GRADE 2, LESS THAN 1t. - MARGINS OF RESECTION ARE FREE OF TUMOR. - NIRPLE FREE OF TUMOR. TWO. OF. TWENTY-SIX (2/26) LEFT AXILLARY LYMPH NODES INVOLVED WITH TUMOR, LARGEST LYMPH NODE 2.3 CM IS. REPLACED BY TUMOR. NOTE: ER/PR immunoperoxidase assay and Her-2/NEU testing was performed on block "A6". Cross. refer. ESTROGEN/PROGESTERONE AND HER-2/NEU REPORT. Using appropriate positive and negative controls, the test for the presence of these hormone receptor. proteins is performed by the immunoperoxidase method, and reported according to the. consensus statement. on adjuvant therapy for breast cancer, of. A positive ER or PR tumo. anows any nuclear. immunostaining, and is semiquantitated as indicated below. Result Semiquantitative Statement. ER positive Percent cells staining as: (0- 0% 1+ 10%; 2+ 10%; 3+ 80%). PR positive Percent cells staining as: (0- or; 1+ or; 2+ 10%; 3+ 90%). HER-2/NEU - DAKO HERCEPTEST: A FAINT/BARELY PERCEPTIBLE MEMBRANE STAINING IS DETECTED IN MORE THAN 10% OF. THE TUMOR CELLS. THE CELLS ARE ONLY STAINED IN PART OF THEIR MEMBRANE. HER-2/NEU IS INTERPRITED AS NEGATIVE. (SCORE 1+). NOTE: The Her-2/NEU and estrogen assays were performed with FDA approved. methods The progesterone. receptor immunoperoxidase test used in this case has been developed and the performance characteristics. determined by the Department of Pathology at. They have not been. cleared or approved by the U.S. Food and Drug Actministration.

expanded version (tokens=1070) : 
 The breast pathology report describes the presence of infiltrating ductal carcinoma ("A2-A7") and ductal carcinoma in-situ, solid type, nuclear grade 2. The cancer is classified as Luminal A subtype. The tumor measures 4.5 by 4.5 by 3.5 cm and has invaded the deep dermis, as evidenced by lymphovascular permeation. The histological grade of the infiltrating ductal carcinoma is Nottingham 6/9, indicating a moderately differentiated tumor with tubules graded 3, nuclei graded 2, and mitosis graded 1. Necrosis is not mentioned in the report.

Two out of twenty-six left axillary lymph nodes are involved with the tumor, and the largest lymph node, measuring 2.3 cm, is replaced by the tumor. The margins of resection are free of tumor, and the nipple is free of tumor as well.

The report mentions that the Estrogen Receptor (ER)/Progesterone Receptor (PR) immunoperoxidase assay and HER-2/NEU testing were performed on block "A6." The ER and PR tests were positive, with about 80% of cells staining for ER and about 90% of cells staining for PR. The HER-2/NEU test was negative, with a score of 1+.

No mention is made of tumor-infiltrating lymphocytes, calcification, or other ancillary testing results. The report

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=1253) : 
 Breast pathology report indicates a Luminal A subtype breast cancer with infiltrating ductal carcinoma and ductal carcinoma in-situ. The tumor has invaded the deep dermis, measuring 4.5 by 4.5 by 3.5 cm and is moderately differentiated with tubules graded as 3, nuclei graded as 2, and mitosis graded as 1. ER/PR tests were positive, HER-2/NEU test was negative. Lymphovascular permeation is observed, but necrosis is not mentioned. Two out of twenty-six axillary lymph nodes are involved with the tumor, and margins resected are free of the tumor

